Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 20;39(1):119–128. doi: 10.3892/or.2017.6102

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Huang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Knockdown of EPS8 increases sensitivity to chemotherapy. K562 cells and their derivatives (1×10⁴ cells/100 µl/well) were added to 96-well culture plates and treated with the indicated concentrations of (A) daunorubicin and (B) imatinib for 48 h. Viability was assessed with the CCK-8 assay. (C) EPS8 expression in 32D-p210-WT and 32D-p210-T315I cells were assessed by western blotting. LV-EPS8-shRNA1 and LV-EPS8-shRNA2 vectors were transfected into 32D-p210-T315I cells, respectively. EPS8 expression was revealed in 32D-p210-T315I-shRNA1-EPS8, T315I-shRNA2-EPS8, and the control cell lines. (D and E) 32D-p210-T315I cells and their derived cells (1×10⁴ cells/100 µl/well) were added to 96-well culture plates and treated with the indicated concentrations of imatinib for (D) 24 h and (E) 48 h, respectively. Viability was assessed with the CCK-8 assay. Plots are representative of 3 independent experiments. ***P<0.001 vs. the scramble control.